×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Events
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Ovarian Cancer

Featured Content
Dr Shannon Westin, a clinical investigator at the MD Anderson Cancer Center, discusses PARP inhibition for patients with deleterious or suspected deleterious germline BRCA-mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.
Katie Kosko
PARP inhibitors show promise in lengthening the life of women with breast cancer, and they're willing to bear the side effects of the treatment. 
Katie Kosko
These targeted therapies fight disease by stopping the fix-it process in damaged cancer cells.
 
Kristie L. Kahl and Lisa Schlager
Lisa Schlager, vice president of public policy at FORCE: Facing Our Risk Empowered, offered background on the differences between genetic testing and a direct-to-consumer test, and why patients should be careful when using over-the counter genetic tests.
Debu Tripathy, M.D.
PARP Inhibitors are opening new doors in cancer treatment by targeting vulnerabilities in cancer that researchers are beginning to understand better.
Arelene Weintraub
PARP inhibitors interfere with cancer’s ability to repair damage to its DNA. They are becoming increasingly useful in treating ovarian cancer.
Julie Grisham
Investigators are studying a rare ovarian tumor called sclerosing stromal tumor, a benign tumor that can be misdiagnosed as cancer.

 
Jessica Skarzynski
Take a look back at the top five CURE® stories for January 2020.
 
Conor Killmurray
From NFL Hall of Famer Kurt Warner leading a recognition service for cancer caregivers during the Super Bowl to Tylenol’s key ingredient possibly being added to California’s proposition 65 list for chemicals that may cause cancer, here’s what is making headlines in the cancer space this week.
Kristie L. Kahl
In this week’s episode, a pair who is forever connected by their genetic risk for cancer talked about the revelations that came from a study they participated in that changed both of their lives.
Sherry B. Hanson
One cancer survivor details how her immunotherapy changed her cancer journey for the better, and how ongoing trials of immunotherapy are looking to change the cancer landscape for the better.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×